El Paso-based biopharmaceutical company Premier Biomedical, Inc. is continuing to develop and commercialize the company’s innovative immune-system manipulation therapies, having in February announced positive pre-clinical data from a breast cancer study for its anti-breast cancer treatment, which was presented at the American Association for Cancer Research Annual Meeting. Now, Premier has announced that it is partnering with another El Paso-based biotech firm — a technology spin-off company from the University of Texas at El Paso (UTEP), Printed Device Concepts, Inc. (PDC) — to collaborate on designing new equipment to advance the company’s upcoming clinical trial schedule.
The agreement between the two companies will lead to the design and fabrication of a novel, patent-pending Sequential Dialysis Machine that Premier says is critical to further development of their medications and procedures that target some of the most difficult and, at-present, incurable diseases, such as breast cancer, Alzheimer’s disease, ALS, multiple sclerosis (MS), and traumatic brain injury (TBI) — all of which are indications that Premier Biomedical targeted in its pre-clinical research and development. In anticipation of new clinical trials, which are expected to begin in 2014, Premier will bring this technology together with its dozen or so United States and E.U. pending provisional patent applications for its therapies.
According to a company press release, “Design progress meetings between Premier Biomedical, Inc. (PBI) and Printed Device Concepts are being held coincident with PBI’s other R&D partners,” which include, “the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center (WBAMC) and the University of Texas at El Paso (UTEP).” Premier Biomedical CEO, William A. Hartman, characterized the new agreement with Printed Device Concepts as a key step in moving Premier’s R&D plans forward: “We have taken a strategically important step with Printed Device Concepts to design and build an actual working version of this patent-pending device. It is anticipated that this first machine will be a fully functioning machine that will not only permit us to support planned near-term clinical trials of our revolutionary technology, but will also serve as a test-bed prototype for more cost-effective versions we intend to put into production to support commercialization of our technology for more effectively treating diseases.”
For their part, Printed Device Concepts President Dan W. Muse highlighted his organization’s eagerness to work on Premier’s audacious, new technology, and noted that the recent agreement with Premier is a major step forward: “We are honored to take part in the development of such a profound technology. The project with Premier is critical to our growth and the diversity of our services. The collaboration will ultimately benefit both companies by reducing to practice some of the most revolutionary medical therapies ever proposed while enabling manufacturing and technology job growth in the border region, which has seen significant investment in infrastructure, and where technology stakeholders and talent are plentiful.”